Pangaea Oncology, S.A. (BME: PANG)

Market Cap	59.62M
Revenue (ttm)	9.95M
Net Income (ttm)	-4.66M
Shares Out	34.07M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	1.770
Previous Close	1.750
Day's Range	1.770 - 1.770
52-Week Range	1.470 - 1.770
Beta	0.07
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2024

About Pangaea Oncology

Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, such as mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnost...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2006
• Employees: 149
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PANG

Financial Performance

In 2023, Pangaea Oncology's revenue was 9.95 million, an increase of 49.12% compared to the previous year's 6.68 million. Losses were -4.66 million, 71.7% more than in 2022.